{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:55:45Z","timestamp":1784343345452,"version":"3.55.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.23708","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T17:09:51Z","timestamp":1658855391000},"page":"e2223708","source":"Crossref","is-referenced-by-count":26,"title":["Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"5","author":[{"given":"Annie Y.","family":"Chen","sequence":"first","affiliation":[{"name":"RAND Corporation, Boston, Massachusetts"},{"name":"Pardee RAND Graduate School, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Powell","sequence":"additional","affiliation":[{"name":"RAND Corporation, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"1","key":"zoi220670r1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics.","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"issue":"32","key":"zoi220670r2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic\u2014United States, June 24-30, 2020.","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"zoi220670r5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2020.17477","article-title":"Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic.","volume":"324","author":"Ochalek","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"zoi220670r6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi220670r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi220670r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108011","article-title":"Appointment wait-times and arrival for patients at a low-barrier access addiction clinic.","volume":"114","author":"Roy","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi220670r9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance.","volume":"63","author":"Schwartz","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"zoi220670r10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugalcdep.2006.04.017","article-title":"A randomized controlled trial of interim methadone maintenance: 10-month follow-up.","volume":"86","author":"Schwartz","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi220670r12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/00952990.2021.1903023","article-title":"Common themes in early state policy responses to substance use disorder treatment during COVID-19.","volume":"47","author":"Andraka-Christou","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"zoi220670r15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.amepre.2018.01.034","article-title":"Trends in medical use of opioids in the US, 2006-2016.","volume":"54","author":"Piper","year":"2018","journal-title":"Am J Prev Med"},{"key":"zoi220670r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.","volume":"131","author":"Brothers","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi220670r17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: opioid use disorder and COVID-19.","volume":"173","author":"Alexander","year":"2020","journal-title":"Ann Intern Med"},{"key":"zoi220670r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108394","article-title":"The impact of COVID-19 on opioid treatment program (OTP) services: where do we go from here?","volume":"131","author":"Tracy","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi220670r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic.","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi220670r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108384","article-title":"Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic.","volume":"129","author":"Cantor","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"23","key":"zoi220670r21","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic.","volume":"324","author":"Huskamp","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"zoi220670r22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ajad.2010.19.issue-1","article-title":"Indicators of buprenorphine and methadone use and abuse: what do we know?","volume":"19","author":"Maxwell","year":"2010","journal-title":"Am J Addict"},{"issue":"5","key":"zoi220670r25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use.","volume":"9","author":"Kampman","year":"2015","journal-title":"J Addict Med"},{"key":"zoi220670r26","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211028262","article-title":"Pronounced regional disparities in United States methadone distribution.","author":"Furst","journal-title":"Ann Pharmacother"},{"issue":"23","key":"zoi220670r28","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2020.22154","article-title":"Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic.","volume":"324","author":"Cance","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"zoi220670r29","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1007\/s11606-021-07083-y","article-title":"Buprenorphine dispensing in Pennsylvania during the COVID-19 pandemic, January to October 2020.","volume":"36","author":"Chalasani","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"7","key":"zoi220670r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada.","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi220670r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108552","article-title":"Changes in methadone take-home dosing before and after COVID-19.","volume":"133","author":"Amram","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi220670r32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/pds.v29.6","article-title":"Rise and regional disparities in buprenorphine utilization in the United States.","volume":"29","author":"Pashmineh Azar","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi220670r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.0093","article-title":"Trends in engagement with opioid use disorder treatment among Medicaid beneficiaries during the COVID-19 pandemic.","volume":"3","author":"Tilhou","year":"2022","journal-title":"JAMA Health Forum"},{"key":"zoi220670r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108655","article-title":"\u201cNo home to take methadone to\u201d: experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.","volume":"135","author":"Harris","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"13","key":"zoi220670r35","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states.","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"zoi220670r36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis.","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"key":"zoi220670r3","unstructured":"National Center for Health Statistics, Centers for Disease Control and Prevention. Provisional drug overdose death surveillance. May 23, 2022. Accessed June 21, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/provisional-drug-overdose.htm"},{"key":"zoi220670r4","unstructured":"Goodnough? A. Overdose deaths have surged during the pandemic, CDC data shows. The New York Times. April 14, 2021. Accessed November 17, 2021. https:\/\/www.nytimes.com\/2021\/04\/14\/health\/overdose-deaths-fentanyl-opiods-coronaviurs-pandemic.html?"},{"key":"zoi220670r11","unstructured":"Substance Abuse and Mental Health Service Administration (SAMHSA). Opioid treatment program (OTP) guidance. Updated March 19, 2020. Accessed August 2, 2021. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf"},{"key":"zoi220670r13","unstructured":"The Substance Abuse and Mental Health Service Administration (SAMHSA). FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. Updated April 1, 2020. Accessed April 8, 2022. https:\/\/www.samhsa.gov\/sites\/default\/files\/faqs-for-oud-prescribing-and-dispensing.pdf"},{"key":"zoi220670r14","unstructured":"Drug Enforcement Administration, US Department of Justice. Use of telephone evaluations to initiate buprenorphine prescribing. March 31, 2020. Accessed April 8, 2022. https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf"},{"key":"zoi220670r23","unstructured":"Drug Enforcement Administration Diversion Control Division. Automation of Reports and Consolidated Orders System (ARCOS). US Dept of Justice. Updated April 5, 2022. Accessed November 15, 2021. https:\/\/www.deadiversion.usdoj.gov\/arcos\/retail_drug_summary\/"},{"key":"zoi220670r24","unstructured":"Federal Reserve Bank of St Louis. Population [B230RC0Q173SBEA]. Updated April 28, 2022. Accessed December 5, 2021. https:\/\/fred.stlouisfed.org\/series\/B230RC0Q173SBEA"},{"key":"zoi220670r27","unstructured":"US Census Bureau. 2019 National and state population estimates. Revised October 8, 2021. Accessed December 5, 2021. https:\/\/www.census.gov\/newsroom\/press-kits\/2019\/national-state-estimates.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2794637\/chen_2022_oi_220670_1658244607.8417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T17:09:54Z","timestamp":1658855394000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2794637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.23708","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}